NMDP BioTherapies Enhances Cell Therapy Services
NMDP BioTherapies, formerly known as Be The Match BioTherapies, is making significant strides in the world of cell and gene therapy. This dynamic organization has unveiled a new and improved suite of premium services aimed at supporting the developers of autologous cell therapies. Recognizing the complexities faced by its clients, NMDP BioTherapies is committed to delivering exceptional service tailored to meet the needs of its customer base.
Addressing Industry Challenges
Transitioning towards autologous cell therapies can be challenging, and industry leaders have continuously expressed the complexities surrounding regulatory requirements and operational processes. Tom Hochuli, the CEO and President of NMDP BioTherapies, emphasizes the company’s mission to alleviate these challenges by providing comprehensive end-to-end support. Their aim is to create a streamlined process that thoroughly addresses the needs of patients and the intricacies of therapy development.
Comprehensive Autologous Cell Therapy Solutions
The suite of new services introduced by NMDP BioTherapies promises consistency across all critical phases of cell therapy—from collection and packaging to logistics and delivery. Their experienced team has successfully onboarded and trained over 165 apheresis centers globally. These centers are integral to managing the logistics of cell therapy, ensuring that all procedures are conducted with utmost care and efficiency.
Balancing Quality and Cost
As Jeni Newman, senior director of operations, notes, the enhancement of services is a balancing act between quality and cost. These two critical aspects are essential for the successful implementation of cell and gene therapies that benefit both developers and patients alike. Moreover, NMDP BioTherapies is dedicated to maintaining a cost-effective model that allows for access to premium services without compromising quality.
Leveraging Experience for Better Outcomes
NMDP BioTherapies is uniquely positioned to support clients through its rich history and extensive knowledge in cell therapy. Since its inception in 2016, it has leveraged its expertise in building and managing a national network dedicated to apheresis. The organization has facilitated the successful delivery of over 130,000 life-saving therapies, demonstrating its capability in managing complex logistical requirements efficiently.
Upcoming Industry Events
In conjunction with the relaunch of their services, members of the NMDP BioTherapies team are scheduled to attend the upcoming Cell & Gene Meeting on the Mesa. This event is pivotal for industry stakeholders, providing an excellent networking opportunity aimed at advancing the potential of cell therapies.
About NMDP BioTherapies
NMDP BioTherapies stands as the only provider offering customizable solutions designed to navigate the full spectrum of the cell therapy supply chain. Backed by decades of expertise and a solid research partnership with the Center for International Blood and Marrow Transplant Research, NMDP BioTherapies is poised to revolutionize the development of crucial therapies. Their commitment to patient access ensures that high-quality cellular material is readily available, further amplifying the advancement of global cell and gene therapies.
Utilizing strong partnerships with apheresis centers and hospitals worldwide, NMDP BioTherapies is developing and managing expansive networks to facilitate progress in cell therapies. Their infrastructure not only supports regulatory compliance but also features logistics experts dedicated to successfully delivering these life-saving therapies.
Frequently Asked Questions
What services has NMDP BioTherapies recently enhanced?
NMDP BioTherapies has unveiled a suite of premium services tailored to developers of autologous cell and gene therapies to support collection, logistics, and delivery.
How does NMDP BioTherapies ensure compliance?
They utilize a proven infrastructure of regulatory compliance specialists and logistics managers to ensure all therapies meet necessary regulations throughout transport.
When will NMDP BioTherapies be participating in industry events?
The organization will attend the 2024 Cell & Gene Meeting on the Mesa, providing a platform for networking and discussion around advancements in cell therapies.
What experience does NMDP BioTherapies have in cell therapy?
Since its establishment in 2016, NMDP BioTherapies has effectively managed over 130,000 life-saving cell therapies and supports over 165 apheresis centers globally.
How does NMDP BioTherapies support patient access to treatments?
They provide high-quality cellular source material and manage extensive networks to ensure timely delivery of therapies to patients in need.
